{
    "hands_on_practices": [
        {
            "introduction": "Accurately estimating prognosis is a cornerstone of palliative decision-making, yet it is a notoriously difficult clinical skill. To move beyond subjective intuition, validated tools like the Palliative Prognostic (PaP) score provide an objective framework for predicting short-term survival. This exercise  challenges you to apply such a score, translating a patient's clinical profile into a quantitative risk category to better inform discussions about the appropriateness of invasive interventions.",
            "id": "4675920",
            "problem": "A general surgery service is considering whether to perform an invasive decompressive procedure for malignant large-bowel obstruction in a patient with disseminated colorectal cancer, versus pursuing non-operative measures and Hospice referral. To structure decision-making at end of life, the team plans to use the Palliative Prognostic Score (PaP). The PaP is an additive point score derived from multivariable logistic regression in palliative oncology cohorts, where each clinical variable contributes a fixed weight to a linear predictor that stratifies the predicted probability of survival at $30$ days. The following variables and point weights are established at your institution based on prior validation studies:\n\n- Dyspnea: present adds $2.0$ points; absent adds $0$ points.\n- Anorexia: present adds $1.5$ points; absent adds $0$ points.\n- Karnofsky Performance Status (KPS), expressed as a fraction from $0$ to $1$ (with $1$ representing 100%), contributes:\n  - $0.70$ to $1.00$: $0$ points,\n  - $0.50$ to $0.60$: $1.5$ points,\n  - $0.30$ to $0.40$: $2.5$ points,\n  - $0.10$ to $0.20$: $4.0$ points.\n- Clinical Prediction of Survival (CPS) in weeks contributes:\n  - $>12$ weeks: $0$ points,\n  - $7$ to $11$ weeks: $2.0$ points,\n  - $3$ to $6$ weeks: $3.5$ points,\n  - $\\le 2$ weeks: $5.5$ points.\n- White Blood Cell (WBC) count in $\\times 10^{9}\\!/\\text{L}$ contributes:\n  - $\\le 8.5$: $0$ points,\n  - $8.6$ to $11.0$: $1.0$ points,\n  - $>11.0$: $2.5$ points.\n- Lymphocyte fraction (absolute lymphocyte count divided by total WBC) contributes:\n  - $\\ge 0.20$: $0$ points,\n  - $0.12$ to $0.199$: $0.8$ points,\n  - $<0.12$: $2.0$ points.\n\nPaP risk groups for $30$-day survival are defined by the total score:\n- Group A: PaP $\\le 5.5$,\n- Group B: PaP $5.6$ to $11.0$,\n- Group C: PaP $>11.0$.\n\nA $68$-year-old patient presents with malignant obstruction and the following clinical profile prior to decision-making:\n- Dyspnea due to a symptomatic malignant pleural effusion (present),\n- Anorexia (present),\n- KPS (fraction) of $0.40$,\n- CPS by the most experienced attending surgeon is $\\le 2$ weeks,\n- WBC count of $12.4 \\times 10^{9}\\!/\\text{L}$,\n- Lymphocyte fraction of $0.08$.\n\nStarting from the principle that validated additive clinical risk scores represent the linear component of a logistic regression model for short-term survival, compute the PaP score by summing the appropriate point contributions from the variables above. Interpret the resulting PaP category in terms of predicted $30$-day survival and remark briefly on how such categorization should inform whether to pursue invasive surgical palliation versus non-operative measures. Express the final PaP score as a dimensionless number and round your answer to three significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in established clinical prognostic scoring systems, is well-posed with all necessary data provided, and is framed in objective, verifiable terms. The task is to calculate a Palliative Prognostic Score (PaP) for a given patient and interpret its implications for clinical decision-making.\n\nThe Palliative Prognostic Score (PaP) is an additive score, which we can denote as $S_{\\text{PaP}}$. It is a linear combination of weighted clinical variables. The total score is the sum of the points contributed by each variable:\n$$S_{\\text{PaP}} = S_{\\text{dyspnea}} + S_{\\text{anorexia}} + S_{\\text{KPS}} + S_{\\text{CPS}} + S_{\\text{WBC}} + S_{\\text{lymph}}$$\nwhere each term $S_i$ represents the point value for a specific clinical variable $i$. We will now determine the value for each term based on the patient's clinical profile.\n\nThe patient is a $68$-year-old with disseminated colorectal cancer. The clinical data are as follows:\n- Dyspnea is present.\n- Anorexia is present.\n- Karnofsky Performance Status (KPS) is $0.40$.\n- Clinical Prediction of Survival (CPS) is $\\le 2$ weeks.\n- White Blood Cell (WBC) count is $12.4 \\times 10^{9}\\!/\\text{L}$.\n- Lymphocyte fraction is $0.08$.\n\nWe will now assign points for each variable according to the scoring system provided.\n\n1.  **Dyspnea:** The patient has dyspnea. According to the rules, the presence of dyspnea contributes $2.0$ points.\n    $$S_{\\text{dyspnea}} = 2.0$$\n\n2.  **Anorexia:** The patient has anorexia. The presence of anorexia contributes $1.5$ points.\n    $$S_{\\text{anorexia}} = 1.5$$\n\n3.  **Karnofsky Performance Status (KPS):** The patient's KPS is $0.40$. This value falls into the category \"$0.30$ to $0.40$,\" which contributes $2.5$ points.\n    $$S_{\\text{KPS}} = 2.5$$\n\n4.  **Clinical Prediction of Survival (CPS):** The attending surgeon's CPS is $\\le 2$ weeks. This prognosis corresponds to a contribution of $5.5$ points.\n    $$S_{\\text{CPS}} = 5.5$$\n\n5.  **White Blood Cell (WBC) Count:** The patient's WBC count is $12.4 \\times 10^{9}\\!/\\text{L}$. This value is greater than $11.0 \\times 10^{9}\\!/\\text{L}$ ($12.4 > 11.0$). This corresponds to a contribution of $2.5$ points.\n    $$S_{\\text{WBC}} = 2.5$$\n\n6.  **Lymphocyte Fraction:** The patient's lymphocyte fraction is $0.08$. This value is less than $0.12$ ($0.08 < 0.12$). This corresponds to a contribution of $2.0$ points.\n    $$S_{\\text{lymph}} = 2.0$$\n\nNow, we sum these point contributions to calculate the total PaP score, $S_{\\text{PaP}}$:\n$$S_{\\text{PaP}} = 2.0 + 1.5 + 2.5 + 5.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 3.5 + 2.5 + 5.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 6.0 + 5.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 11.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 14.0 + 2.0$$\n$$S_{\\text{PaP}} = 16.0$$\n\nThe total PaP score for this patient is $16.0$. The problem requests this value rounded to three significant figures, which $16.0$ already satisfies.\n\nNext, we interpret this score by classifying the patient into a risk group. The defined groups are:\n- Group A: PaP $\\le 5.5$\n- Group B: PaP $5.6$ to $11.0$\n- Group C: PaP $> 11.0$\n\nSince the calculated score is $S_{\\text{PaP}} = 16.0$, which is greater than $11.0$, the patient falls into **Group C**.\n\nFinally, we remark on the implications for clinical decision-making. The problem states that the PaP score stratifies the predicted probability of survival at $30$ days. Group C represents the cohort with the highest scores and, consequently, the lowest predicted probability of $30$-day survival. In the context of deciding between invasive surgical palliation (e.g., decompressive colectomy) and non-operative measures (e.g., symptom management and Hospice care), a very poor prognosis as indicated by a Group C PaP score is a critical factor. The principle of proportionality suggests that the significant physiological stress, morbidity, potential for complications, and recovery time of a major invasive procedure are likely to outweigh the potential benefits of palliating the obstruction in a patient whose expected survival is extremely short. Therefore, a high PaP score strongly supports a recommendation against aggressive surgical intervention and in favor of a focus on quality of life, symptom control, and end-of-life care planning with Hospice services. The score provides an objective, data-driven foundation for this difficult and sensitive clinical discussion.",
            "answer": "$$\\boxed{16.0}$$"
        },
        {
            "introduction": "Effective symptom management is central to providing high-quality palliative care, and transitioning a patient's pain regimen from an inpatient to an outpatient setting is a frequent and high-stakes task. This problem  provides a practical application of the core pharmacological principles of opioid rotation, including equianalgesic dosing and adjusting for incomplete cross-tolerance. Mastering this calculation is essential for ensuring patient safety and comfort during a critical phase of care.",
            "id": "4675896",
            "problem": "A patient with advanced malignant bowel obstruction under palliative care is being transitioned from inpatient intravenous (IV) opioid therapy to an oral regimen in preparation for home hospice. Over the last $24$ hours, the patient received a continuous infusion of intravenous morphine at $2.5$ $\\text{mg/hour}$ and additional Patient-Controlled Analgesia (PCA) boluses totaling $18$ $\\text{mg}$. The plan is to rotate to oral oxycodone and design a schedule that maintains analgesia while mitigating risk at discharge.\n\nUse the following well-tested facts from equianalgesic dosing and rotation principles:\n- $10$ $\\text{mg}$ intravenous morphine is approximately equivalent to $30$ $\\text{mg}$ oral morphine.\n- $30$ $\\text{mg}$ oral morphine is approximately equivalent to $20$ $\\text{mg}$ oral oxycodone.\n- To account for incomplete cross-tolerance when switching opioids, reduce the calculated equianalgesic daily dose of the new opioid by 33%.\n- For safety at discharge, schedule 85% of the reduced daily oxycodone dose evenly every $4$ hours, reserving the remaining $15\\%$ for breakthrough dosing.\n\nDerive from first principles the scheduled oral oxycodone dose per administration every $4$ hours. Express the final answer in $\\text{mg}$ and round your answer to two significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in established principles of clinical pharmacology, well-posed, objective, and contains all necessary information to derive a unique solution.\n\nThe primary objective is to calculate the scheduled oral oxycodone dose, administered every $4$ hours, for a patient transitioning from intravenous (IV) morphine. The derivation proceeds in a sequence of logical steps, starting from the current total daily dose of IV morphine.\n\nStep 1: Calculate the Total Daily Dose (TDD) of IV Morphine.\nThe patient's total consumption of IV morphine over the last $24$ hours is the sum of the dose from the continuous infusion and the dose from Patient-Controlled Analgesia (PCA) boluses.\n\nLet $D_{\\text{IV-M,total}}$ be the total daily dose of IV morphine.\nThe dose from the continuous infusion is the rate multiplied by the duration:\n$$D_{\\text{infusion}} = 2.5 \\, \\text{mg/hour} \\times 24 \\, \\text{hours} = 60 \\, \\text{mg}$$\nThe dose from PCA boluses is given as:\n$$D_{\\text{PCA}} = 18 \\, \\text{mg}$$\nThe TDD of IV morphine is the sum of these two amounts:\n$$D_{\\text{IV-M,total}} = D_{\\text{infusion}} + D_{\\text{PCA}} = 60 \\, \\text{mg} + 18 \\, \\text{mg} = 78 \\, \\text{mg}$$\n\nStep 2: Convert the TDD of IV Morphine to the Equianalgesic TDD of Oral Morphine.\nThe problem provides the conversion factor: $10$ mg of IV morphine is equivalent to $30$ mg of oral morphine. The conversion ratio from IV to oral morphine is therefore:\n$$C_{\\text{IV-M} \\to \\text{O-M}} = \\frac{30 \\, \\text{mg oral morphine}}{10 \\, \\text{mg IV morphine}} = 3$$\nLet $D_{\\text{O-M,total}}$ be the equianalgesic TDD of oral morphine.\n$$D_{\\text{O-M,total}} = D_{\\text{IV-M,total}} \\times C_{\\text{IV-M} \\to \\text{O-M}} = 78 \\, \\text{mg} \\times 3 = 234 \\, \\text{mg}$$\n\nStep 3: Convert the TDD of Oral Morphine to the Equianalgesic TDD of Oral Oxycodone.\nThe problem provides the conversion factor: $30$ mg of oral morphine is equivalent to $20$ mg of oral oxycodone. The conversion ratio from oral morphine to oral oxycodone is:\n$$C_{\\text{O-M} \\to \\text{O-Oxy}} = \\frac{20 \\, \\text{mg oral oxycodone}}{30 \\, \\text{mg oral morphine}} = \\frac{2}{3}$$\nLet $D_{\\text{O-Oxy,initial}}$ be the initial calculated equianalgesic TDD of oral oxycodone.\n$$D_{\\text{O-Oxy,initial}} = D_{\\text{O-M,total}} \\times C_{\\text{O-M} \\to \\text{O-Oxy}} = 234 \\, \\text{mg} \\times \\frac{2}{3} = 156 \\, \\text{mg}$$\n\nStep 4: Apply Dose Reduction for Incomplete Cross-Tolerance.\nTo ensure safety when rotating between opioids, the calculated dose is reduced to account for incomplete cross-tolerance. The required reduction is $33\\%$. The remaining dose fraction is $100\\% - 33\\% = 67\\%$, or $0.67$.\nLet $D_{\\text{O-Oxy,reduced}}$ be the reduced TDD of oral oxycodone.\n$$D_{\\text{O-Oxy,reduced}} = D_{\\text{O-Oxy,initial}} \\times (1 - 0.33) = 156 \\, \\text{mg} \\times 0.67 = 104.52 \\, \\text{mg}$$\n\nStep 5: Calculate the Scheduled Daily Dose of Oral Oxycodone.\nThe regimen specifies that $85\\%$ of the reduced TDD is for scheduled doses, and the remaining $15\\%$ is for breakthrough pain.\nLet $D_{\\text{O-Oxy,scheduled}}$ be the total daily scheduled dose of oral oxycodone.\n$$D_{\\text{O-Oxy,scheduled}} = D_{\\text{O-Oxy,reduced}} \\times 0.85 = 104.52 \\, \\text{mg} \\times 0.85 = 88.842 \\, \\text{mg}$$\n\nStep 6: Calculate the Scheduled Dose Per Administration.\nThe scheduled dose is administered every $4$ hours. The number of administrations in a $24$-hour period is:\n$$N_{\\text{doses}} = \\frac{24 \\, \\text{hours}}{4 \\, \\text{hours/dose}} = 6 \\, \\text{doses}$$\nLet $d_{\\text{scheduled}}$ be the dose per administration. This is the total daily scheduled dose divided by the number of doses.\n$$d_{\\text{scheduled}} = \\frac{D_{\\text{O-Oxy,scheduled}}}{N_{\\text{doses}}} = \\frac{88.842 \\, \\text{mg}}{6} = 14.807 \\, \\text{mg}$$\n\nStep 7: Round to the Required Significant Figures.\nThe problem requires the final answer to be rounded to two significant figures. The calculated value is $14.807$. The first two significant figures are $1$ and $4$. The third digit is $8$, which is greater than or equal to $5$, so we round up the second digit.\n$$d_{\\text{scheduled,rounded}} \\approx 15 \\, \\text{mg}$$\nThe scheduled oral oxycodone dose per administration every $4$ hours is $15$ mg.",
            "answer": "$$\\boxed{15}$$"
        },
        {
            "introduction": "Deciding among different palliative interventions requires a careful balancing of procedural risks, potential for symptom relief, and impact on quality of life. Decision analysis provides a powerful tool to structure these complex choices and compare them quantitatively from a patient-centered perspective. In this final practice , you will construct and evaluate a decision tree to determine the optimal strategy for a patient with malignant gastric outlet obstruction, integrating probabilities and quality-of-life utilities to calculate the expected value of each option.",
            "id": "4675944",
            "problem": "A patient with unresectable malignant gastric outlet obstruction is at the end of life and faces three palliative strategy options: endoscopic duodenal stenting, surgical gastrojejunostomy bypass, and best supportive care. To evaluate these options using expected utility grounded in Quality-Adjusted Life Month (QALM) principles, consider the following scientifically plausible and self-consistent model. Assume each strategy yields a decision tree with four terminal health states: complication, symptom relief without reintervention, symptom relief with reintervention, and no symptom relief. Expected utility is the probability-weighted sum of terminal-state QALMs. Use the definitions of expected value and QALM as the fundamental base: QALM equals the product of time in a health state and the health-state utility weight, and expected utility equals the sum over branches of branch probability times branch QALM.\n\nFor endoscopic duodenal stenting, assume the following branch probabilities: complication $0.12$; if no complication, probability of symptom relief $0.80$; among those with symptom relief, probability of reintervention $0.50$. Thus, the implied terminal state probabilities are: complication $0.12$; symptom relief without reintervention $0.88 \\times 0.80 \\times (1 - 0.50)$; symptom relief with reintervention $0.88 \\times 0.80 \\times 0.50$; no symptom relief $0.88 \\times (1 - 0.80)$. The terminal-state QALM components are: complication survival $2.0$ months at utility weight $0.20$; symptom relief survival $4.0$ months at utility weight $0.75$; no relief survival $2.5$ months at utility weight $0.40$; reintervention hospitalization lasts $0.5$ months at utility weight $0.15$, with the remaining symptom-relief months at utility weight $0.75$.\n\nFor surgical gastrojejunostomy bypass, assume branch probabilities: complication $0.20$; if no complication, probability of symptom relief $0.90$; among those with symptom relief, probability of reintervention $0.10$. Thus, terminal state probabilities are: complication $0.20$; symptom relief without reintervention $0.80 \\times 0.90 \\times (1 - 0.10)$; symptom relief with reintervention $0.80 \\times 0.90 \\times 0.10$; no symptom relief $0.80 \\times (1 - 0.90)$. The terminal-state QALM components are: complication survival $2.5$ months at utility weight $0.15$; symptom relief survival $5.0$ months at utility weight $0.80$; no relief survival $3.0$ months at utility weight $0.45$; reintervention hospitalization lasts $1.0$ month at utility weight $0.15$, with the remaining symptom-relief months at utility weight $0.80$.\n\nFor best supportive care, assume branch probabilities: complication $0.05$; if no complication, probability of symptom relief $0.30$; among those with symptom relief, probability of reintervention $0.40$. Thus, terminal state probabilities are: complication $0.05$; symptom relief without reintervention $0.95 \\times 0.30 \\times (1 - 0.40)$; symptom relief with reintervention $0.95 \\times 0.30 \\times 0.40$; no symptom relief $0.95 \\times (1 - 0.30)$. The terminal-state QALM components are: complication survival $1.5$ months at utility weight $0.25$; symptom relief survival $3.0$ months at utility weight $0.60$; no relief survival $2.0$ months at utility weight $0.35$; reintervention hospitalization lasts $0.3$ months at utility weight $0.15$, with the remaining symptom-relief months at utility weight $0.60$.\n\nUsing first principles of expected utility and QALM, compute the expected utility in Quality-Adjusted Life Months (QALMs) for each of the three strategies, then determine the maximum expected utility among the three strategies. Express the final utility in QALMs and round your answer to four significant figures.",
            "solution": "The problem requires the calculation of the expected utility for three palliative strategies—endoscopic duodenal stenting (EDS), surgical gastrojejunostomy bypass (SGB), and best supportive care (BSC)—and the identification of the strategy with the maximum expected utility. The utility is measured in Quality-Adjusted Life Months (QALM). The problem statement is scientifically grounded, well-posed, and self-consistent, thus it is valid.\n\nThe fundamental principle is the calculation of expected utility, $E[U]$, which is the sum of the utilities of all possible outcomes, each weighted by its probability of occurrence.\n$$E[U] = \\sum_{i} P_i \\times U_i$$\nwhere $P_i$ is the probability of outcome $i$ and $U_i$ is the utility (in QALM) of outcome $i$. The utility is defined as Quality-Adjusted Life Months (QALM), calculated as the product of the duration of a health state in months ($T$) and the utility weight ($W$) of that state:\n$$QALM = T \\times W$$\nIf a health state consists of multiple periods with different utility weights, the total QALM is the sum of the QALMs for each period.\n\nThe four terminal health states for each strategy are: complication ($C$), symptom relief without reintervention ($SR_0$), symptom relief with reintervention ($SR_1$), and no symptom relief ($NS$). We will calculate the expected utility for each of the three strategies.\n\n**1. Endoscopic Duodenal Stenting (EDS)**\n\nFirst, we calculate the probabilities for the four terminal states for EDS.\nThe probability of a complication is given as $P(C)_{EDS} = 0.12$.\nThe probability of no complication is $1 - 0.12 = 0.88$.\nThe probability of symptom relief without reintervention is $P(SR_0)_{EDS} = (1-P(C)) \\times P(\\text{relief}|\\text{no C}) \\times (1-P(\\text{reint}|\\text{relief})) = 0.88 \\times 0.80 \\times (1 - 0.50) = 0.352$.\nThe probability of symptom relief with reintervention is $P(SR_1)_{EDS} = (1-P(C)) \\times P(\\text{relief}|\\text{no C}) \\times P(\\text{reint}|\\text{relief}) = 0.88 \\times 0.80 \\times 0.50 = 0.352$.\nThe probability of no symptom relief is $P(NS)_{EDS} = (1-P(C)) \\times (1-P(\\text{relief}|\\text{no C})) = 0.88 \\times (1 - 0.80) = 0.176$.\nThe sum of probabilities is $0.12 + 0.352 + 0.352 + 0.176 = 1.0$.\n\nNext, we calculate the QALM for each state.\n$QALM(C)_{EDS}$: $2.0$ months at utility $0.20$.\n$$QALM(C)_{EDS} = 2.0 \\times 0.20 = 0.40$$\n$QALM(SR_0)_{EDS}$: $4.0$ months at utility $0.75$.\n$$QALM(SR_0)_{EDS} = 4.0 \\times 0.75 = 3.0$$\n$QALM(NS)_{EDS}$: $2.5$ months at utility $0.40$.\n$$QALM(NS)_{EDS} = 2.5 \\times 0.40 = 1.0$$\n$QALM(SR_1)_{EDS}$: Total survival of $4.0$ months, composed of $0.5$ months hospitalization at utility $0.15$ and $(4.0 - 0.5) = 3.5$ months at utility $0.75$.\n$$QALM(SR_1)_{EDS} = (0.5 \\times 0.15) + (3.5 \\times 0.75) = 0.075 + 2.625 = 2.70$$\nFinally, we calculate the expected utility for EDS.\n$$E[U]_{EDS} = P(C)_{EDS} \\times QALM(C)_{EDS} + P(SR_0)_{EDS} \\times QALM(SR_0)_{EDS} + P(SR_1)_{EDS} \\times QALM(SR_1)_{EDS} + P(NS)_{EDS} \\times QALM(NS)_{EDS}$$\n$$E[U]_{EDS} = (0.12 \\times 0.40) + (0.352 \\times 3.0) + (0.352 \\times 2.70) + (0.176 \\times 1.0)$$\n$$E[U]_{EDS} = 0.048 + 1.056 + 0.9504 + 0.176 = 2.2304$$\n\n**2. Surgical Gastrojejunostomy Bypass (SGB)**\n\nWe repeat the process for SGB.\nProbabilities: $P(C)_{SGB} = 0.20$. No complication is $1 - 0.20 = 0.80$.\n$P(SR_0)_{SGB} = 0.80 \\times 0.90 \\times (1 - 0.10) = 0.648$.\n$P(SR_1)_{SGB} = 0.80 \\times 0.90 \\times 0.10 = 0.072$.\n$P(NS)_{SGB} = 0.80 \\times (1 - 0.90) = 0.08$.\nThe sum of probabilities is $0.20 + 0.648 + 0.072 + 0.08 = 1.0$.\n\nQALMs for SGB:\n$QALM(C)_{SGB} = 2.5 \\times 0.15 = 0.375$.\n$QALM(SR_0)_{SGB} = 5.0 \\times 0.80 = 4.0$.\n$QALM(NS)_{SGB} = 3.0 \\times 0.45 = 1.35$.\n$QALM(SR_1)_{SGB}$: $1.0$ month hospitalization at utility $0.15$ and $(5.0 - 1.0) = 4.0$ months at utility $0.80$.\n$$QALM(SR_1)_{SGB} = (1.0 \\times 0.15) + (4.0 \\times 0.80) = 0.15 + 3.20 = 3.35$$\nExpected utility for SGB:\n$$E[U]_{SGB} = (0.20 \\times 0.375) + (0.648 \\times 4.0) + (0.072 \\times 3.35) + (0.08 \\times 1.35)$$\n$$E[U]_{SGB} = 0.075 + 2.592 + 0.2412 + 0.108 = 3.0162$$\n\n**3. Best Supportive Care (BSC)**\n\nWe repeat the process for BSC.\nProbabilities: $P(C)_{BSC} = 0.05$. No complication is $1 - 0.05 = 0.95$.\n$P(SR_0)_{BSC} = 0.95 \\times 0.30 \\times (1 - 0.40) = 0.171$.\n$P(SR_1)_{BSC} = 0.95 \\times 0.30 \\times 0.40 = 0.114$.\n$P(NS)_{BSC} = 0.95 \\times (1 - 0.30) = 0.665$.\nThe sum of probabilities is $0.05 + 0.171 + 0.114 + 0.665 = 1.0$.\n\nQALMs for BSC:\n$QALM(C)_{BSC} = 1.5 \\times 0.25 = 0.375$.\n$QALM(SR_0)_{BSC} = 3.0 \\times 0.60 = 1.80$.\n$QALM(NS)_{BSC} = 2.0 \\times 0.35 = 0.70$.\n$QALM(SR_1)_{BSC}$: $0.3$ months hospitalization at utility $0.15$ and $(3.0 - 0.3) = 2.7$ months at utility $0.60$.\n$$QALM(SR_1)_{BSC} = (0.3 \\times 0.15) + (2.7 \\times 0.60) = 0.045 + 1.62 = 1.665$$\nExpected utility for BSC:\n$$E[U]_{BSC} = (0.05 \\times 0.375) + (0.171 \\times 1.80) + (0.114 \\times 1.665) + (0.665 \\times 0.70)$$\n$$E[U]_{BSC} = 0.01875 + 0.3078 + 0.18981 + 0.4655 = 0.98186$$\n\n**4. Comparison and Final Answer**\n\nWe compare the expected utilities of the three strategies:\n$E[U]_{EDS} = 2.2304$ QALM\n$E[U]_{SGB} = 3.0162$ QALM\n$E[U]_{BSC} = 0.98186$ QALM\n\nThe maximum expected utility is provided by the surgical gastrojejunostomy bypass (SGB) strategy.\n$$ \\max(E[U]_{EDS}, E[U]_{SGB}, E[U]_{BSC}) = \\max(2.2304, 3.0162, 0.98186) = 3.0162 $$\nThe problem requires the answer to be rounded to four significant figures.\nThe value $3.0162$ rounded to four significant figures is $3.016$.",
            "answer": "$$\\boxed{3.016}$$"
        }
    ]
}